Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.

Merck KGaA in talks to acquire SpringWorks Therapeutics for $47/share ($3.5B), gaining cancer drugs Ogsiveo and Gomekli. Deal ...

HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...

A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...

Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...

Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...

In an interview with PBS' 'NewsHour' co-anchor and co-managing editor Amna Nawaz on Thursday, Marty Makary expanded on his ...

When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing ...

ALX On­col­o­gy’s ef­forts to progress a CD47 com­bo hit a ma­jor speed bump. The com­pa­ny said Fri­day that two tri­als ...

Nicholas Johnston launches Alis Biosciences, targeting struggling biotechs with $30B in trapped capital and aiming to return cash to shareholders.

Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer ...

Only 66% of FDA-approved biosimilars launched, with Humira & Enbrel facing limited competition despite biosimilars priced ...